Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00492531
• Other study ID #: 070177
• Secondary ID: 07-H-0177
• Status: Terminated
• Phase: Phase 2
• First received: June 26, 2007
• Last updated: December 7, 2015
• Start date: June 2007
• Est. completion date: October 2009

Study information

• Verified date: December 2015
• Source: National Heart, Lung, and Blood Institute (NHLBI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high blood pressure in the lungs). It will see if this treatment can reduce disease complications, such as shortness of breath, pain crisis, pneumonia, and increase survival.

Patients 12 years of age and older with sickle cell disease and pulmonary hypertension may be eligible for this study. Participants are randomly assigned to receive sildenafil or placebo (sugar pill) for 16 weeks. Before starting treatment, patients have baseline studies, including a pregnancy test for females of childbearing age; a chest x-ray; pulmonary function tests to measure how much air the patient can breathe in and out; an echocardiogram (heart ultrasound); a 6-minute walk test to measure exercise capacity; a quality-of-life assessment and a pain inventory. Patients with moderate to severe pulmonary hypertension undergo heart catheterization to evaluate the severity of hypertension before beginning sildenafil therapy.

During treatment, patients are monitored with the following:

• Blood tests: weeks 6, 10 and 16.

• Echocardiogram: weeks 6 and 16.

• 6-minute walk test: weeks 6, 10 and 16.

• Measurements of weight, blood pressure and heart rate: weeks 6, 10 and 16.

• Pregnancy test for women of childbearing age: weeks 6, 10 and 16.

• Pain questionnaire once a day for a week: weeks 6 and 1.0

• Quality-of-life questionnaire: week 16.

• Heart catheterization: week 16 for patients with moderate to severe hypertension.

At the end of the 16-week period, patients may opt to continue to receive sildenafil and monitoring in an open-label phase of the study for up to 1 year.

Description:

Sickle cell disease (SCD) is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15 percent of African-Americans are homozygous for sickle cell disease, and 8 percent have sickle cell trait. Acute pain crisis, acute chest syndrome (ACS), and pulmonary hypertension are common complications of sickle cell anemia. Pulmonary hypertension (PH) has now been identified as a marker of mortality in adults with sickle cell disease. Sildenafil has been proven beneficial in pulmonary hypertension (PH) and recent phase I/II studies from the intramural National Institutes of Health (NIH) suggest it is well tolerated and efficacious in the SCD population. Furthermore, a number of recent studies have suggested that nitric oxide (NO) based therapies may have a favorable impact on sickle red cells at the molecular level and could improve the abnormal microvascular perfusion that is characteristic of sickle cell anemia.

The project has 3 distinct components:

1. Screening Phase. Approximately 1000 subjects with sickle cell disease will be screened. Assessments will include historical and laboratory data, Doppler echocardiogram, 6-minute walk test, plasma/serum, and DNA for banking.

2. Main Interventional Trial. The randomized, double-blind, placebo controlled phase is designed to determine the effects of 16 weeks of Sildenafil therapy on exercise endurance, cardiopulmonary hemodynamic parameters and symptoms in this patient population. The open-label follow-up phase is designed to provide up to an additional year of Sildenafil therapy to subjects who completed the randomized, double-blind phase.

3. Observational Follow-up Study. Screened patients who do not qualify for participation in the main interventional trial may be contacted every 6-12 months for up to 3 years to assess major disease-related complications, including mortality.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 74
• Est. completion date: October 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years to 70 Years

Eligibility

• Eligibility based on the following inclusion and exclusion criteria.

INCLUSION CRITERIA:

Screening Phase:

• Males or females, greater than or equal to 12 years of age and less than or equal to 70 years of age.

• Diagnosis of sickle cell disease (including, but not limited to SS, SC, SD, or S-beta zero thalassemia).

• Provision of informed consent and, where applicable, assent.

Observational Follow-up Study:

• Satisfaction of screening criteria.

• In the opinion of the investigator, ability to maintain follow-up contact.

• Failure to satisfy the eligibility requirements of the Main Interventional Trial (MIT) OR discontinuation/completion of the MIT/Open-label Follow-up Phase.

• Provision of informed consent and, where applicable, assent.

Main Interventional Trial:

• Males or females, 12 years of age or older and less than or equal to 70 years of age.

• Female subjects, on a reliable method of birth control or not physically able to bear children.

• Electrophoretic documentation of sickle cell disease (including, but not limited to SS, SC, SD, or S-beta zero thalassemia).

• At least mild pulmonary hypertension with TRV greater than or equal to 2.7 m/sec by echocardiogram.

• Six-minute walk distance of 150-500 m.

• In the opinion of the investigator, able to complete the protocol scheduled assessments during the 16-week, double-blind phase.

• Provision of informed consent and, where applicable, assent.

• Subjects with systemic hypertension must be on a stable antihypertensive regimen for greater than or equal to 90 days and a stable dose for greater than or equal to 30 days.

EXCLUSION CRITERIA:

Current pregnancy or lactation.

Any one of the following medical conditions:

• Stroke within the last six weeks.

• Diagnosis of pulmonary embolism within the last three months.

• History of retinal detachment or retinal hemorrhage in the last 6 months.

• Non-arteritic anterior ischemic optic neuropathy (NAION) in one or both eyes.

• History of sustained priapism requiring medical or surgical treatment, unless currently impotent or on transfusion program within the last two years.

• Any unstable (chronic or acute) condition that in the opinion of the investigator will prevent completion of the study.

Subjects taking nitrate-based vasodilators (including, but not limited to nicorandil [available in the UK only]), prostacyclin (inhaled, subcutaneous or intravenous) or endothelin antagonists. Subjects taking calcium channel blockers will be allowed to participate if they are on a stable dose for greater than or equal to 3 months.

Left ventricular ejection fraction (LVEF) less than 40 percent or clinically significant ischemic, valvular or constrictive heart disease: LVEF less than 40 percent or SF less than 22 percent.

Subjects in other research studies with investigational drugs (with the exception of hydroxyurea) unless the other trial has been approved by the walk-PHaSST Executive Committee for co-participation.

Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent claudication, symptomatic hip osteonecrosis.

Tonsillectomies for sleep apnea within 3 months prior to randomization. Active therapy for pulmonary hypertension, including prostacyclin analog, endothelin-1 antagonist, or PDE-5 inhibitor.

Protease inhibitor therapy for HIV treatment Subjects taking potent CYP3A4 inhibitor therapy (e.g., itraconazole, ritonavir, ketoconazole) Subjects who are anticoagulated and have proliferative retinopathy (unless they have had ophthalmologist recommended intervention (e.g., phototherapy) or have been cleared by the ophthalmologist to participate in the study.

Subjects with systolic blood pressure greater than or equal to 140 mmHg OR diastolic blood pressure greater than or equal to 90 mmHg.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension
• Sickle Cell Disease

Intervention

Drug:
• Sildenafil
Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
• Placebo
Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.

Locations

Country	Name	City	State
United Kingdom	Imperial College London and Hammersmith Hospital	London
United States	Johns Hopkins University	Baltimore	Maryland
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland
United States	Albert Einstein College of Medicine	Bronx	New York
United States	University of Illinois at Chicago	Chicago	Illinois
United States	University of Colorado	Denver	Colorado
United States	Children's Hospital, Oakland	Oakland	California
United States	Childrens Hospital, Pittsburgh	Pittsburgh	Pennsylvania
United States	Howard University Hospital	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Countries where clinical trial is conducted

United States,  United Kingdom, 

References & Publications (3)

Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am. 1996 Dec;10(6):1289-303. Review. — View Citation

Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994 Sep 15;74(6):626-8. — View Citation

Verresen D, De Backer W, Vermeire P. Pulmonary hypertension and sickle hemoglobinopathy. Chest. 1990 Oct;98(4):1042. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Exercise Capacity as Assessed by 6 Minute Walk.	The primary outcome measure was change in exercise capacity assessed by 6 minute walk distance in meters from baseline to 16 weeks. Subjects without a week 16 assessment had their last observation carried forward.	Baseline to week 16/Imputed last visit.	No
Secondary	Change From Baseline in Pulmonary Hypertension at Week 16 as Assessed by Tricuspid Regurgitant Jet Velocity	Secondary outcome measure was change from baseline in Pulmonary hypertension at week 16 as assessed by Tricuspid regurgitant jet velocity(TRV). Tricuspid regurgitant jet velocity was measured by transthoracic Doppler Echocardiography.	16 weeks	No
Secondary	Borg Dyspnea Score	Borg dyspnea score was used to measure the level of severity of breathlessness perceived by the patient before and after 6 minute walk. The severity is measured on a 10 point scale with 0= nothing at all and 10=maximum severity of breathlessness.	baseline to 16 weeks	No
Secondary	Brain Natriuretic Peptide(BNP)Levels.		16 weeks	No

External Links

•   NIH Clinical Center Detailed Web Page